Pharmaceutical composition for preventing and treating epilepsy, dyskinesia, or neurodegenerative diseases, comprising olivetol or pharmaceutically acceptable salt thereof as active ingredient

Olivetol-based compositions address the challenge of neurodegenerative and epilepsy treatments by protecting brain cells and reducing oxidative stress, effectively preventing and treating these conditions in optimal concentrations, thus improving quality of life and reducing medical burdens.

WO2024248585A1PCT designated stage expired Publication Date: 2024-12-05IND ACADEMIC COOPERATION FOUND JEJU NAT UNIVERSTIY +1
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2024/095799
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-06-01
Filing Date
2024-05-17
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

The rapid increase in neurodegenerative diseases and epilepsy due to aging and environmental factors poses a significant challenge in finding effective prevention and treatment solutions, as current treatments are inadequate in managing these conditions, which lead to severe neurological disorders and substantial medical costs.

Method used

A pharmaceutical or food composition containing olivetol or its pharmaceutically/foodologically acceptable salts, which is used to protect brain nerve cells, reduce intracellular reactive oxygen species, inhibit oxidative stress, and regulate motility, thereby preventing, improving, or treating epilepsy and neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's disease.

Benefits of technology

The composition effectively reduces excessive motility and oxidative stress, protects brain nerve cells, and improves or prevents epilepsy and neurodegenerative diseases, as demonstrated by its efficacy in zebrafish models, with optimal concentrations between 0 and 60uM, ensuring safety and effectiveness without toxicity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2024095799_05122024_PF_FP_ABST
    Figure KR2024095799_05122024_PF_FP_ABST
Patent Text Reader

Abstract

The present disclosure relates to a pharmaceutical composition for preventing and treating epilepsy, dyskinesia, or neurodegenerative diseases, comprising olivetol or a pharmaceutically acceptable salt thereof as an active ingredient. The pharmaceutical composition can reduce intracellular reactive oxygen species, reduce excessive mobility in a zebrafish model of epilepsy, and inhibit glutamate-induced oxidative stress and apoptosis.
Need to check novelty before this filing date? Find Prior Art

Description

Pharmaceutical composition for the prevention and treatment of epilepsy, movement disorders or degenerative neurological diseases, comprising olivetol or a pharmaceutically acceptable salt thereof as an active ingredient

[0001] Cross-reference to related applications

[0002] This application claims the benefit of priority to Korean Patent Application No. 2023-0070648, filed June 1, 2023, the contents of which are incorporated herein by reference in their entirety.

[0003] The present disclosure relates to a pharmaceutical composition for the prevention and treatment of epilepsy, movement disorders or degenerative neurological diseases, comprising olivetol or a pharmaceutically acceptable salt thereof as an active ingredient.

[0004] Advances in medicine have led to a rapidly aging population, and rapid industrialization has led to environmental pollution, leading to a sharp increase in the incidence of movement disorders and degenerative neurological diseases, such as Alzheimer's, Parkinson's, and Huntington's. Movement disorders are neurological disorders that cause abnormal postures and movements, such as Parkinson's disease, ataxia, chorea, dystonia, and gait disturbances. Furthermore, the occurrence of degenerative neurological diseases can lead to fatal neurological disorders, which not only lower the quality of life but also exacerbate the psychological and economic burden caused by the enormous burden of medical expenses. Therefore, solutions are urgently needed to address these issues.

[0005] Meanwhile, epilepsy is a disease characterized by recurrent seizures caused by a variety of factors, including developmental disorders, genetic and environmental factors, and a complex pathogenesis. Congenital genetic mutations and malformations, brain cell migration disorders, birth injury, intracerebral hemorrhage, intracranial inflammation, febrile seizures, hypoxia, hypoglycemia, hypocalcemia, brain trauma, intracranial tumors, and cerebrovascular disease can all cause epilepsy. Idiopathic epilepsy, for which the cause is unknown, is also present.

[0006] The present inventors have confirmed that olivetol, or a pharmaceutically or food-based acceptable salt thereof, protects brain neurons, regulates zebrafish motility, and suppresses excessive motility in a genetically epileptic zebrafish model. Based on these results, the inventors have confirmed that olivetol, or a pharmaceutically or food-based acceptable salt thereof, can prevent, improve, or treat epilepsy or other neurodegenerative diseases, thereby completing the present invention.

[0007] The problem to be solved by the present disclosure is to provide a pharmaceutical composition or food composition comprising olivetol, or a pharmaceutically or food-wise acceptable salt thereof, as an active ingredient, which can prevent, treat, and improve epilepsy or a degenerative neurological disease.

[0008] One aspect of the present disclosure is a pharmaceutical composition for preventing and treating epilepsy or a degenerative neurological disease, comprising olivetol or a pharmaceutically acceptable salt thereof as an active ingredient.

[0009] In the present disclosure, the concentration of olivetol or a pharmaceutically acceptable salt thereof may be greater than 0 uM and less than or equal to 60 uM.

[0010] In the present disclosure, the movement disorder and neurodegenerative disease may be selected from the group consisting of Alzheimer's disease, Parkinson's disease, frontotemporal dementia, Lewy body dementia, and Huntington's chorea.

[0011] Another aspect of the present disclosure is a food composition for preventing and improving epilepsy or a degenerative neurological disease, comprising olivetol or a food-based acceptable salt thereof as an active ingredient.

[0012] In the present disclosure, the food may be a health functional food.

[0013] In the present disclosure, the concentration of olivetol or a food-based acceptable salt thereof may be greater than 0 uM and less than or equal to 60 uM.

[0014] The present disclosure provides the use of Olivetol or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition for the prevention and treatment of epilepsy, movement disorders or degenerative neurological diseases.

[0015] The present disclosure provides the use of olivetol or a food-acceptable salt thereof for the preparation of a plant composition for preventing and improving epilepsy, movement disorders or degenerative neurological diseases.

[0016] The composition according to the present disclosure can reduce intracellular reactive oxygen species (ROS), regulate the motility of zebrafish, and inhibit oxidative stress and apoptosis induced by glutamate, thereby improving, preventing, and treating neurodegenerative diseases.

[0017] In addition, the composition according to the present disclosure can reduce excessive motility in a zebrafish epilepsy model, thereby improving, preventing, and treating epilepsy and movement disorders.

[0018] Figure 1 is a graph showing cytotoxicity according to the concentration of olebetol.

[0019] Figure 2 is a diagram showing the cell death rate according to the concentration of olebetol.

[0020] Figure 3 is a diagram showing the active oxygen inhibition effect according to the concentration of olivetol.

[0021] Figure 4 is a diagram showing the results of zebrafish development according to the concentration of olivetol.

[0022] Figure 5 is a graph showing the heart rate of zebrafish according to the concentration of olivetol.

[0023] Figure 6 is a diagram showing the motility of zebrafish according to the concentration of olivetol.

[0024] Figure 7 is a diagram showing the movement distance of zebrafish according to the concentration of olivetol.

[0025] Figure 8 is a diagram showing the excessive motor inhibition levels of a zebrafish model of epilepsy according to the concentration of olivetol.

[0026] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains. In general, the nomenclature used herein and the experimental methods described below are well known and commonly used in the art.

[0027] The present inventors confirmed that olivetol can protect brain neurons, suppress excessive motility in a zebrafish epilepsy model, reduce intracellular reactive oxygen species, and inhibit oxidative stress and apoptosis induced by glutamate.

[0028] Additionally, the present inventors confirmed that olivetol can reduce excessive motility in a zebrafish epilepsy model.

[0029] The present disclosure is a pharmaceutical composition for the prevention and treatment of epilepsy, movement disorders or degenerative neurological diseases, comprising olivetol or a pharmaceutically acceptable salt thereof as an active ingredient.

[0030] In the present disclosure, olivetol can be represented by the following chemical formula 1.

[0031] [Chemical Formula 1]

[0032]

[0033] The composition of the present disclosure may be used for epilepsy, movement disorders, or degenerative neurological diseases without limitation, and specifically, the degenerative neurological diseases may be selected from the group consisting of Alzheimer's disease, Parkinson's disease, frontotemporal dementia, Lewy body dementia, and Huntington's chorea.

[0034] In this disclosure, epilepsy is a chronic disease characterized by recurrent seizures due to abnormal hyperexcitation and hypersynchrony of the brain, causing some neurons to generate excessive electrical impulses in a short period of time. It is a serious neurological disorder that entails neurobiological, psychological, cognitive, and social changes. Furthermore, unlike common neurological disorders that manifest as cognitive and behavioral impairments due to neuronal degeneration or death, epilepsy is a neurological disorder that occurs due to abnormal, excessive activation of neurons.

[0035] Alzheimer's disease is a neurodegenerative disorder that results in the loss of cortical neurons, particularly in the neocortex and hippocampus, leading to a slow or progressive loss of cognitive function and ultimately to dementia and death.

[0036] Parkinson's disease is a chronic, neurodegenerative disorder of muscle movement characterized by the selective degeneration of nigrostriatal neurons, which significantly reduce their ability to synthesize dopamine and, consequently, fail to connect to striatal dopamine receptors. Meanwhile, dyskinetic disorders are neurological disorders that cause abnormal postures and movements, including parkinsonism, ataxia, chorea, dystonia, and gait disturbances.

[0037] Frontotemporal dementia is a type of degenerative dementia that occurs due to pathological changes limited to the frontal lobe at the front of the brain and the temporal lobe at the lower side, resulting in a decline in the function of the frontal lobe and temporal lobe. It is a type of degenerative neurological disease.

[0038] Lewy body dementia is a type of dementia characterized by the widespread development of acidophilic intracytoplasmic inclusion bodies (Lewy bodies) throughout the brain. Lewy body dementia is the second most common cause of dementia after Alzheimer's disease, accounting for 10-25% of all dementia cases. It is a type of degenerative neurodegenerative disease.

[0039] Huntington's disease is a genetic, degenerative neurological disorder characterized by involuntary physical movements as well as mental and cognitive abnormalities.

[0040] In the present disclosure, the concentration of olivetol, or a pharmaceutically or food-wise acceptable salt thereof, may be greater than 0 uM and less than or equal to 60 uM, preferably 5 to 50 uM, and more preferably 5 to 40 uM. Referring to the examples, if the concentration of olivetol, or a pharmaceutically or food-wise acceptable salt thereof, exceeds 60 uM, it may be toxic to the heart of zebrafish, and therefore the above range is preferred.

[0041] In the present disclosure, olivetol, or a pharmaceutically or food-wise acceptable salt thereof, can protect brain neurons, suppress cytotoxicity, reduce intracellular ROS, and, when referring to the examples, can reduce excessive motility in a zebrafish model of epilepsy without affecting normal development in zebrafish. Accordingly, it can prevent, improve, or treat neurodegenerative diseases.

[0042] Additionally, in the present disclosure, olivetol, or a pharmaceutically or food-wise acceptable salt thereof, can reduce excessive motility in a zebrafish model of epilepsy, as described in the examples, thereby preventing, improving, or treating epilepsy.

[0043] As used herein, the term "pharmaceutically acceptable salt" refers to any salt that retains the desired biological and / or physiological activity of olivetol while minimizing undesirable toxicological effects. It refers to a salt prepared according to methods conventional in the art, such preparation methods being well known to those skilled in the art.

[0044] Specifically, pharmaceutically acceptable salts include, but are not limited to, salts derived from pharmacologically or physiologically acceptable inorganic and organic acids and bases.

[0045] For example, pharmaceutically acceptable base addition salts can be prepared from inorganic and organic bases. Salts derived from inorganic bases can include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, and magnesium salts, and salts derived from organic bases can include, but are not limited to, primary, secondary, and tertiary amines; substituted amines, including naturally occurring substituted amines; And salts of cyclic amines including isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-dimethylaminoethanol, tromethamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, N-alkylglucamines, theobromine, purines, piperazine, piperidine, and / or N-ethylpiperidine. In addition, carboxylic acid amides including other carboxylic acid derivatives, for example, carboxamides, lower alkyl carboxamides, di(lower alkyl)carboxamides, etc. may also be included.

[0046] For example, pharmaceutically acceptable acid addition salts can be prepared from inorganic and organic acids. Salts derived from inorganic acids include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Salts derived from organic acids can include, but are not limited to, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, and / or salicylic acid.

[0047] The composition of the present disclosure may further comprise suitable carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions.

[0048] The composition of the present disclosure can be formulated and used in the form of oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc., external preparations, suppositories, and sterile injection solutions, respectively, according to conventional methods, and carriers, excipients, and diluents that can be included in the composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil. When formulated, it is usually prepared using diluents or excipients such as fillers, bulking agents, binders, wetting agents, disintegrating agents, and surfactants. Solid preparations for oral administration include tablets, pills, powders, granules, and capsules, and these solid preparations are prepared by mixing the extract with at least one excipient, such as starch, calcium carbonate, sucrose or lactose, gelatin, etc. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral administration include suspensions, oral solutions, emulsions, and syrups, and in addition to commonly used simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, and suppositories. Non-aqueous solutions and suspensions can include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. Suppository bases include witepsol, macrogol, Tween 61, cacao butter, laurin, and glycerogelatin.

[0049] The composition of the present disclosure can be administered to mammals, such as rats, mice, livestock, and humans, via various routes. All modes of administration are contemplated, and for example, administration can be by oral, rectal, intravenous, intramuscular, subcutaneous, intrauterine, or intracerebroventricular injection.

[0050] In addition, the present disclosure relates to a food composition for preventing and improving epilepsy, movement disorders or degenerative neurological diseases, comprising olivetol or a food-scientifically acceptable salt thereof as an active ingredient, and the food may be a health functional food.

[0051] In the present disclosure, a "food-acceptable salt" may be an acid addition salt formed by a food-acceptable free acid, or a metal salt formed by a base. The free acid may be an inorganic acid or an organic acid. The inorganic acid may include hydrochloric acid, sulfuric acid, hydrobromic acid, sulfurous acid, or phosphoric acid, and the organic acid may include citric acid, acetic acid, maleic acid, fumaric acid, gluconic acid, or methanesulfonic acid. In addition, the metal salt may include, but is not necessarily limited to, an alkali metal salt or an alkaline earth metal salt, sodium, potassium, or calcium salt.

[0052] The composition of the present disclosure can be used in various foods and beverages for the prevention and improvement of epilepsy, movement disorders, or degenerative neurological diseases. Health functional foods to which the composition of the present disclosure can be added include, for example, various foods, beverages, gum, tea, meat, chocolate, confectionery, ice cream, vitamin complexes, and health supplements, and can be used in the form of powder, granules, tablets, capsules, or beverages.

[0053] In this disclosure, the term “health functional food” refers to a food manufactured and processed using raw materials or ingredients with functionality useful to the human body as defined in Act No. 6727 on Health Functional Foods, and is meant to be consumed for the purpose of obtaining beneficial effects for health purposes such as regulating nutrients for the structure and function of the human body or physiological effects.

[0054] The health functional food of the present disclosure may contain conventional food additives, and its suitability as a food additive is determined by the specifications and standards for the relevant item in accordance with the general provisions and general test methods of the Food Additive Code approved by the Ministry of Food and Drug Safety, unless otherwise provided.

[0055] In addition to the above, the composition of the present disclosure may contain various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavoring agents and natural flavoring agents, coloring agents and thickening agents (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. In addition, the composition of the present disclosure may contain fruit pulp for the production of natural fruit juices, fruit juice drinks, and vegetable drinks. These ingredients may be used independently or in combination.

[0056] The present disclosure provides the use of Olivetol or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition for the prevention and treatment of epilepsy or a neurodegenerative disease.

[0057] The present disclosure provides the use of olivetol or a food-grade acceptable salt thereof for the preparation of a plant composition for preventing and improving epilepsy or a neurodegenerative disease.

[0058] In the present disclosure, the terms “epilepsy”, “movement disorder”, “degenerative neurological disease”, “food-acceptable salt”, “pharmaceutically acceptable salt”, “olivetol”, “pharmaceutical composition” and “food composition” are as described above.

[0059] Hereinafter, the present disclosure will be described in more detail through examples. These examples are intended solely to illustrate the present disclosure, and it will be apparent to those skilled in the art that the scope of the present disclosure is not limited by these examples.

[0060]

[0061] <Experimental Method>

[0062] 1. Neuroprotective activity

[0063] Cell viability was measured using the wst-1 assay kit. Mouse hippocampal-derived HT22 cells were seeded at 1.5 × 10 in each 24-well plate. 4 Cells were seeded at 10 cells / well and treated with olivetol at concentrations of 5–90 μM after 22 h. Glutamate was added at a concentration of 4 mM 2 h after olivetol treatment. After 24 h, the medium was replaced with 5% wst-1 reagent for cell viability assay and incubated at 37°C in a 5% CO2 incubator for approximately 30 min. After the reaction, absorbance was measured at 450 nm using a multiskan GO spectrophotometer (Thermo Scientific).

[0064]

[0065] 2. Cell death analysis

[0066] To analyze the cell death type, 10 × 10 4HT22 cells were seeded at a density of 10 cells / well in each well of a 6-well plate. After 22 hours, they were treated with 5 μM and 20 μM olivetol, respectively, and 2 hours later, they were treated with 4 mM glutamate for 24 hours. The cells were removed from the wells and the remaining medium was removed with PBS. After resuspending the cells using Annexin-V binding buffer, they were stained with Annexin V and propidium iodide. After incubating them in a 5% CO2 incubator at 37°C for 15 minutes, cell death was measured by flow cytometry.

[0067]

[0068] 3. Measurement of intracellular reactive oxygen species (ROS)

[0069] Intracellular reactive oxygen species were measured using flow cytometry by staining cells with H2DCFDA. 10 × 10 4 HT22 cells were seeded at a density of 10 cells / well in each well of a 6-well plate. After 22 h, the cells were treated with 5 μM and 20 μM olivetol, respectively, and 2 h later, with 4 mM glutamate for 14 h. Subsequently, the cells were incubated with H2DCFDA dye at a concentration of 10 μM for 15 min at 37°C in a 5% CO2 incubator. The cells were removed from the wells, the remaining medium was removed with PBS, and intracellular reactive oxygen species were measured using flow cytometry.

[0070]

[0071] 4. Preparation of zebrafish animal models

[0072] Zebrafish were reared in an automated facility maintained at 28.5°C and a 14-h day / 10-h night photoperiod. Brine shrimp were hatched and fed as food. To obtain fertilized eggs, a male and female pair were placed in a mating cage, and fertilized eggs were collected the following morning. The collected fertilized eggs were then developed in an incubator at 28.5°C.

[0073]

[0074] 5. Developmental toxicity test using zebrafish embryos

[0075] Zebrafish embryos were treated with olivetol to observe cytotoxicity and developmental toxicity. Specifically, embryos 4 hours after fertilization were seeded in 24-well plates (10 embryos per well) and treated with olivetol at concentrations of 5, 10, 20, 30, 40, 50, 60, 70, 80, and 90 μM. 0.1% DMSO was used as a negative control. After 20 hours, the number of dead embryos due to toxicity was counted under a microscope and toxicity was observed.

[0076]

[0077] 6. Zebrafish cardiotoxicity test

[0078] On the third day after fertilization, fry were seeded in 24-well plates (5 per well) and treated with olivetol at concentrations of 5, 10, 20, 30, 40, 50, 60, 70, 80, and 90 μM for 2 hours. 0.1% DMSO was used as a negative control. After 2 hours, heart rate was measured for 1 minute under a microscope.

[0079]

[0080] 7. Zebrafish neurobehavioral analysis

[0081] 1) To evaluate the nervous system effect of olivetol through the motor behavior of zebrafish embryos, a spontaneous tail coiling test (STC test) was performed. Zebrafish embryos 22 hours after fertilization were placed in a 24-well plate and treated with olivetol at concentrations of 5, 10, 20, 30, 40, 50, 60, 70, 80, and 90 μM, respectively. 0.1% DMSO was treated as a negative control. Olivetol was treated for 2 hours, and 10 embryos were analyzed for each concentration. The number of tail movements was measured in zebrafish embryos 24 hours after fertilization.

[0082]

[0083] 2) To evaluate locomotion activity, zebrafish fry 6 days after fertilization were placed one per well in a 24-well plate and treated with olivetol at concentrations of 5, 10, 20, 30, 40, 50, 60, 70, 80, and 90 μM, respectively. 0.1% DMSO was treated as a negative control. Olivetol was treated for 2 hours, and the locomotion activity of three fish per concentration was measured for 15 minutes using DanioVision, an automatic zebrafish behavioral analysis device.

[0084]

[0085] 3) To measure sensory and responsive behavior to external stimuli, a touch-evoked response (TER) evaluation was performed. Zebrafish were treated with olivetol at concentrations of 5, 10, 20, 30, 40, 50, 60, 70, 80, and 90 μM at 48 and 72 hours after fertilization, respectively. 0.1% DMSO was treated as a negative control. Olivetol was treated for 2 hours. Three zebrafish were analyzed for each concentration. Motor responsiveness to stimuli was evaluated by assessing the presence or absence of responsiveness to external stimuli.

[0086]

[0087] 4) To confirm the reversibility of the action of olivetol on animal behavior, zebrafish were placed in 24-well plates (5 per well) on the 4th day after fertilization and treated with olivetol at concentrations of 5, 10, 20, 30, 40, 50, 60, 70, 80, and 90 μM for 2 hours each. 0.1% DMSO was used as a negative control. Afterwards, the fish were washed 10 times for 5 minutes each to remove olivetol. The presence or absence of reactivity was measured by microscopic observation.

[0088]

[0089] 8. Evaluation of the efficacy of olivetol using a zebrafish epilepsy disease model.

[0090] To evaluate the efficacy of olivetol in a zebrafish epilepsy disease model, the epilepsy disease model and analysis method presented in KR 10-1750893 were utilized. To evaluate whether olivetol can suppress excessive jaw movements in an epilepsy disease model, zebrafish epilepsy disease models 5 days after fertilization were seeded in 24-well plates with 3 fish per well and treated with olivetol at concentrations of 5, 10, 20, 30, 40, 50, 60, 70, 80, and 90 uM for 2 hours each, and jaw movements were measured. Wild-type (WT) zebrafish and epilepsy disease model zebrafish (Control KO) were used as controls. 2 hours after olivetol treatment, the number of jaw movements per minute in the control and olivetol-treated groups was measured under a microscope.

[0091]

[0092] 9. Statistical Analysis

[0093] All experimental data were repeated at least three times, and error bars are expressed as mean ± standard deviation (SD). Statistical analysis of data was performed using one-way ANOVA-Tukey's multiple comparison test (GraphPad Prism, version 5.0, Graphpad Software Inc., San Diego, CA). Statistical significance is *** p < 0.001, ** p < 0.01, * p < 0.05 compared to the control group, and ### p < 0.001, ## p < 0.01, # p < 0.05 compared to the group treated only with glutamate.

[0094]

[0095] <Experimental Results>

[0096] 1. Neuroprotective activity

[0097] As shown in Fig. 1A, up to a concentration of 40 uM, there was no significant effect on cell viability, and when treated with a concentration of 90 uM, it was confirmed that cell viability decreased by about 25%. As shown in Fig. 1B, when olivetol was treated simultaneously with glutamate, the cell viability of the glutamate-treated group was found to be about 40%, which was significantly reduced compared to the control group. On the other hand, when 20 uM and 30 uM olivetol were treated with glutamate, it was confirmed that the cell viability significantly increased to over 90%.

[0098]

[0099] 2. Analysis of cell death types

[0100] As shown in Fig. 2, the analysis of cell death by olivetol showed that the cell death level of HT22 cells significantly increased when treated with glutamate compared to the control group, and when olivetol and glutamate were treated simultaneously, the cell death level decreased at both concentrations of 5uM and 20uM.

[0101]

[0102] 3. Measurement of intracellular reactive oxygen species (ROS)

[0103] As shown in Fig. 3, it can be confirmed that the amount of intracellular ROS increased by about 2 times compared to cells not treated with glutamate as a result of glutamate treatment, and when 5uM and 20uM olivetol were treated simultaneously with glutamate, it can be confirmed that intracellular ROS decreased.

[0104]

[0105] 4. Developmental toxicity test using zebrafish embryos

[0106] As shown in Fig. 4, in the groups treated with olivetol at concentrations of 5 to 50 uM, development was apparently normal, and no dead embryos were observed. At 60 uM and 70 uM, zebrafish embryos showing developmental delay were observed (~40%), but survival was not significantly affected. At concentrations of 80 uM and 90 uM, it was confirmed that embryo survival was affected (80 uM: mortality rate 20%, 90 uM: mortality rate 45%).

[0107]

[0108] 5. Zebrafish cardiac toxicity assessment

[0109] As shown in Figure 5, there was no significant effect on heart rate up to a concentration of 60 uM, but it was confirmed that heart rate decreased in a concentration-dependent manner from a high concentration of 70 uM or higher.

[0110]

[0111] 6. Zebrafish neurobehavioral assessment (neurobehaviortest)

[0112] 1) Exercise behavior

[0113] As shown in Figure 6, tail movement was reduced at 5uM, and at concentrations of 10uM or higher, it was confirmed that motility was reduced as tail movement did not occur.

[0114]

[0115] 2) Exercise distance

[0116] As shown in Fig. 7, the movement distance was reduced at 5uM, and at concentrations of 10uM or higher, it was confirmed that the motility was reduced as there was no movement.

[0117]

[0118] 3) Sensation and response to external stimuli

[0119] As shown in Table 1 below, there was a response to stimulation at a concentration of 5uM, but no response was observed at concentrations of 10uM or higher, confirming reduced motility.

[0120] Classification con5uM10uM20uM30uM40uM50uM60uM70uM80uM90uM2nd day occurrence YesYesNoNoNoNoNoNoNoNoNo3rd day occurrence YesYesNoNoNoNoNoNoNoNo

[0121]

[0122] 4) Reversibility of drug action

[0123] As shown in Table 2 below, it can be confirmed that olivetol has reversible drug action except at a concentration of 90 uM.

[0124] Classification con5uM10uM20uM30uM40uM50uM60uM70uM80uM90uM4th day occurrence YesYesYesYesYesYesYesYesYesYesNo

[0125]

[0126] 7. Efficacy of Olivetol in a Zebrafish Epilepsy Disease Model

[0127] As shown in Figure 8, the epilepsy disease model (Control KO) exhibited excessive jaw movements, whereas treatment with 5 μM olivetol regulated motility to a level similar to that of the wild type (WT). Motility was inhibited in the 10-90 μM concentration range.

[0128]

[0129] A composition comprising olivetol according to the present disclosure can be usefully used to improve, prevent, and treat epilepsy, degenerative neurological diseases, or related symptoms.

Claims

1. A pharmaceutical composition for the prevention and treatment of epilepsy, movement disorders or degenerative neurological diseases, comprising olivetol or a pharmaceutically acceptable salt thereof as an active ingredient.

2. In paragraph 1, A pharmaceutical composition for preventing and treating epilepsy or a neurodegenerative disease, wherein the concentration of olivetol or a pharmaceutically acceptable salt thereof is greater than 0uM and less than or equal to 60uM.

3. In paragraph 1, A pharmaceutical composition for the prevention and treatment of epilepsy, movement disorders or degenerative neurological diseases, wherein the above-mentioned degenerative neurological diseases are selected from the group consisting of Alzheimer's disease, Parkinson's disease, frontotemporal dementia, Lewy body dementia and Huntington's chorea.

4. A food composition for preventing and improving epilepsy, movement disorders or degenerative neurological diseases, comprising olivetol or a food-related acceptable salt thereof as an active ingredient.

5. In paragraph 4, The above food is a health functional food, a food composition for preventing and improving epilepsy, movement disorders or degenerative neurological diseases.

6. In paragraph 4, A food composition for preventing and improving epilepsy, movement disorders or degenerative neurological diseases, wherein the concentration of olivetol or a food-related salt thereof is greater than 0uM and less than 60uM.

7. In paragraph 4, A food composition for preventing and improving epilepsy, movement disorders or degenerative neurological diseases, wherein the above-mentioned degenerative neurological diseases are selected from the group consisting of Alzheimer's disease, Parkinson's disease, frontotemporal dementia, Lewy body dementia and Huntington's chorea.

Citation Information

Patent Citations

  • Cannabinoid active pharmaceutical ingredient for improved dosage forms

    KR1020130067323A

  • Energy storage system

    KR1020240047562A

  • Methods related to bioactive agents that convert from anions to molecules

    US20230089351A1

  • Formulation and noncovalent stabilization of olivetolic acid derivatives

    US20230390311A1